NewslettersImmune Regulation NewsA Novel EGFRvIII-T Cell Bispecific Antibody for the Treatment of GlioblastomaBy lbeveridge - August 3, 20220138Scientists designed and developed a novel 2+1 EGFRvIII-TCB with optimal pharmacological characteristics and potent anti-tumor activity.[Molecular Cancer Therapeutics]Abstract